MDGL Earnings & Financial Statements
Madrigal Pharmaceuticals, Inc.
$458.29
-$1.72(-0.37%)
40
Overall
40
Value
36
Tech
44
Quality
Market Cap
$10.63B
Volume
86.10K
52W Range
$393.61 - $615.00
Target Price
$675.50
MDGL earnings and financial statements: Madrigal Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MDGL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $958.40M | $180.13M | - | - | - |
| Cost of revenue | $56.15M | $6.23M | - | - | - |
| Operating income | -$300.10M | -$497.88M | -$380.50M | -$293.57M | -$242.48M |
| EBITDA | -$262.88M | -$448.04M | -$357.98M | -$290.12M | -$241.44M |
| Net income | -$288.30M | -$465.89M | -$373.63M | -$295.35M | -$241.85M |
| EPS (diluted) | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.26B | $1.04B | $640.55M | $362.57M | $273.33M |
| Total liabilities | $656.90M | $287.86M | $235.21M | $165.18M | $77.22M |
| Shareholders’ equity | $602.69M | $754.38M | $405.33M | $197.39M | $196.11M |
| Cash and equivalents | $198.69M | $100.02M | $99.92M | $331.55M | $36.27M |
| Long-term debt | $346.61M | $118.59M | $116.67M | $49.29M | $387.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$189.55M | -$455.57M | -$324.23M | -$224.86M | -$183.92M |
| Capital expenditure | -$3.47M | -$6.46M | -$1.48M | -$217.0K | -$209.0K |
| Free cash flow | -$193.02M | -$462.03M | -$325.71M | -$225.07M | -$184.13M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDGL | $458.29 | -0.4% | 86.10K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Madrigal Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW